Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma

Br J Haematol. 2022 Apr;197(1):e5-e8. doi: 10.1111/bjh.17997. Epub 2021 Dec 20.
No abstract available

Keywords: Hodgkin lymphoma; bone marrow involvement; intensive chemotherapy; positron emission tomography; prognosis.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow / diagnostic imaging
  • Bone Marrow / pathology
  • Clinical Trials as Topic
  • Fluorodeoxyglucose F18 / therapeutic use
  • Hodgkin Disease* / diagnostic imaging
  • Hodgkin Disease* / drug therapy
  • Humans
  • Neoplasm Staging
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography / methods
  • Prognosis
  • Progression-Free Survival

Substances

  • Fluorodeoxyglucose F18